Huntsman Cancer Institute’s CEO and director, Mary Beckerle, PhD, has been asked to join Vice President Joe Biden’s Moonshot Program Initiative as an invited member of a new Blue Ribbon Panel, tasked with advising the National Cancer Advisory Board (NCAB) on the scientific opportunities available to accelerate progress against cancer and evaluate potential new investments in cancer research.
Office of Public Affairs
2000 Circle of Hope,
Salt Lake City, UT 84112
No one plans on having a medical emergency, but if one happens, an advance directive outlines your plans and wishes for medical care. It tells your doctor and your family what decisions to make on your behalf, if you are unable to speak for yourself. An advance directive is also called a living will. Even if you’re young and healthy, you can prepare for unforeseeable events with an advance directive. The forms for an advance directive vary by state, but most follow the same basic format. Learn more about advance directives and Utah advance health care directive forms and instructions from the University of Utah’s Center on Aging.
There are limits to precision medicine – the genome-mapping wave permeating health care these days. And no one is more aware of the gap between technology and science than cancer doctors. A panel gathered at Huntsman Cancer Institute (HCI) March 23 warned about the boundaries, even the dangers, of relying too much on “big data” to treat patients with uniquely variable diseases.
Inheriting a mutation in the APC gene leads to a nearly 100% lifetime risk of colorectal cancer. While colon cancer can be kept at bay by removing the large intestine, these patients also have up to a 15% risk of getting cancer in the small intestine, which is the leading cause of cancer death in this patient group. A new study published in the Journal of the American Medical Association (JAMA), has identified the first prevention treatment for these patients, a two-drug combination that significantly reduces the number and size of precancerous polyps in the small intestine.
The Huntsman 140 is a fundraising road cycling event on Saturday, June 18 in Salt Lake City, Utah. All funds raised through this one-day event go to Huntsman Cancer Foundation (HCF) to support cancer research at Huntsman Cancer Institute (HCI). Each rider is encouraged to fundraise $500 to support cancer research at HCI. This ride is ideal for cyclists of all levels--from avid riders taking on the 140-mile challenge to newer pedalers enjoying the rolling 25-mile course. The variety of courses include 25-, 50-, 75-, and 140-mile routes.
Cancer of unknown primary is a rare disease (3-5% of individuals diagnosed with cancer are diagnosed with a cancer of unknown primary) in which cancer cells have spread in the body but the place the cancer began is unknown. There are a number of reasons why the primary cancer may not be found. The primary tumor may be too small to find, or the body’s immune system may have already destroyed it. It’s also possible that the primary tumor was removed during surgery for another condition and doctors didn’t know the cancer was there. Cancer has a language all its own and it’s that much harder if English is not your first language. That’s where Guadalupe Tovar, a health educator and patient navigator at Huntsman Cancer Institute (HCI), comes in. She helps Hispanic families navigate their cancer care.
Vice President Joe Biden already was thinking about ways to share “big data” across disciplines, hospital systems and state borders in his quest to defeat cancer. But a five-volume gift of his family’s genealogy from leaders of The Church of Jesus Christ of Latter-day Saints, a crash course in the Utah Population Database and a round table discussion with cancer researchers at Huntsman Cancer Institute (HCI) Friday clinched it.
(February 26, 2016) – Today Huntsman Cancer Institute (HCI) hosted Vice President Joe Biden as a part of the White House administration’s “moonshot” initiative to double the rate of progress toward curing cancer. During his visit, the vice president toured the facility, was given an inside look at the Utah Population Database and participated in a roundtable discussion comprised of Huntsman Cancer Foundation board chairman Jon Huntsman Jr., CEO and director of HCI Dr. Mary Beckerle and Senator Orrin Hatch. Local cancer survivors and physicians, researchers and experts in the field also participated in the roundtable.
Even though many HPV-related cancers are preventable with a safe and effective vaccine, HPV vaccination rates across the U.S. remain low.
Prostate cancer is the most common cancer among men. In fact, 1 in 8 men will be diagnosed with prostate cancer during their lifetimes. Many patients receive a diagnosis of prostate cancer and immediately begin to imagine difficult and time-consuming radiation treatments, but Huntsman Cancer Institute is pioneering new technology to help these patients and offering them renewed hope for the future.
Cancer usually begins in one location and then spreads, but in 3-5% of cancer patients, the tissue where a cancer began is unknown. In these individuals a cancer diagnosis is made because it has metastasized to other sites. Patients with these so-called “cancers of unknown primary,” or CUP, have a very poor prognosis, with a median survival of three months. A new study in the Journal of the American Medical Association (JAMA) Oncology finds that family members of CUP patients are at higher risk of developing CUP themselves, as well as cancers of the lung, pancreas, colon, and some cancers of the blood.
Aspirin has been shown to decrease the risk of colorectal cancer and possibly other cancers. However, the risk of side effects, including in some cases severe gastrointestinal bleeding, makes it necessary to better understand the mechanisms by which aspirin acts at low doses before recommending it more generally as a preventative, says Cornelia Ulrich, PhD, Senior Director of Population Sciences at Huntsman Cancer Institute in Salt Lake City.
The U.S. Food and Drug Administration announced October 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the U.S. The drug was approved for use against late stage melanoma, a deadly skin cancer that can be difficult to treat.
Why elephants rarely get cancer is a mystery that has stumped scientists for decades. A study led by researchers at Huntsman Cancer Institute (HCI) at the University of Utah and Arizona State University, and including researchers from the Ringling Bros. Center for Elephant Conservation, may have found the answer.
As part of a multi-institutional effort, researchers with Huntsman Cancer Institute at the University of Utah have found that multiple myeloma patients with a genetic variation in the gene FOPNL die on average 1-3 years sooner than patients without it.
National Cancer Institute Awards Huntsman Cancer Institute Elite Comprehensive Cancer Center Designation - Only such designation in five-state Intermountain West
The National Cancer Institute (NCI) has awarded Huntsman Cancer Institute (HCI) at the University of Utah its Comprehensive Cancer Center status, the highest designation possible.
Study Finds Childhood Cancer Survivors More Likely to Be Enrolled in Social Security Support as Adults
Children with cancer have a good chance of surviving the disease—today more than 80% survive due to advances in treatment and care. However, recent studies have shown that some of these more than 420,000 U.S. childhood cancer survivors face future health related challenges as they become adults such as a second cancer diagnosis, cardiac failure, or other severe medical complications.
Characterization of the Nutrient Needs of Triple Negative Breast Cancer Leads to the Identification of a Molecular Signature for Cancer Outcomes
Compared to other types of breast cancer, triple negative breast cancers are often more aggressive and have fewer treatment options. In a new study published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers at Huntsman Cancer Institute and the University of Utah have identified a molecular mechanism that triple negative breast cancer cells use to survive and grow.
Martin McMahon, Ph.D., joins Huntsman Cancer Institute (HCI) at the University of Utah in August as Professor in the Department of Dermatology and HCI Senior Director of Pre-Clinical Translation. Professor McMahon is currently the Efim Guzik Distinguished Professor of Cancer Biology at the University of California, San Francisco and Assistant Director of Professional Education and Co-leader of the Helen Diller Family Comprehensive Cancer Center (HCFCCC) Developmental Therapeutics Program.
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have found that defects in how cells are squeezed out of overcrowded tissue to die, a process called extrusion, may be a mechanism by which pancreatic cancer begins. From these findings, they may have identified an effective way to reverse the defective extrusion’s effects without destroying normal tissues nearby. The results were published in the latest edition of the journal eLife.
Our media relations representatives are here to help reporters Monday-Friday, 7:30 am-5 pm.
Public Affairs Manager
Public Relations Associate
After-hours calls: Reporters calling before or after business hours on an urgent matter can page the University of Utah Health on-call media relations representative at 801-581-7387 and press 1.